Earnings Call Summary | Cyclacel Pharmaceuticals(CYCC.US) Q1 2024 Earnings Conference
Earnings Call Summary | Cyclacel Pharmaceuticals(CYCC.US) Q1 2024 Earnings Conference
The following is a summary of the Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript:
以下是Cyclacel製藥公司（CYCC）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Cyclacel reported cash and cash equivalents of $9.9 million as of the end of Q1 2024, with net cash used in operating activities substantially down to $0.5 million.
R&D expenses were also significantly down, standing at $2.8 million, leading to a net loss of $2.9 million for Q1 2024.
The company's current cash resources are projected to fund planned programs into the fourth quarter of 2024.
Cyclacel報告稱，截至2024年第一季度末，現金及現金等價物爲990萬美元，其中用於經營活動的淨現金大幅下降至50萬美元。
研發費用也大幅下降，爲280萬美元，導致2024年第一季度淨虧損290萬美元。
該公司目前的現金資源預計將爲2024年第四季度的計劃提供資金。
Business Progress:
業務進展：
Cyclacel has begun dosing patients in Phase 2 of the 065-101 study of fadraciclib for patients with specific chromosomal abnormalities.
Initial results from the study are expected by the second half of 2024.
The company recently raised $8 million in a financing round.
They have identified a substantial unmet medical need and industry interest in patient populations with chromosomal abnormalities CDKN2A and CDKN2B, for which no treatments are currently approved.
Cyclacel已開始在針對特定染色體異常患者的065-101研究的第二階段給患者服藥。
該研究的初步結果預計將在2024年下半年公佈。
該公司最近在一輪融資中籌集了800萬美元。
他們已經確定了患有 CDKN2A 和 CDKN2B 染色體異常的患者群體中存在大量未得到滿足的醫療需求和行業興趣，目前尚未批准任何治療方法。
More details: Cyclacel Pharmaceuticals IR
更多詳情： Cyclacel 製藥公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。